December 2015

pharma courses

16 December 2015

Recruitment for post of Junior Pharmacists (17 posts) at primary health centres under DHS

16 December 2015
Career for Gp Hd PV Quality & Inspection Readiness at Novartis

A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

16 December 2015
Applications invited for faculty posts at Sumandeep Vidyapeeth

Sumandeep Vidyapeeth stands as a testimony to the grit, determination, enthusiasm, vision and ‘never say die’ attitude of Dr. Mansukh Shah, a dentist and a philanthropist, who dared to dream big and translate it into reality. A man of humble beginnings, with sheer persistence he has converted a patch of barren land into a sprawling, pulsating educational centre. Starting with a small clinic with two dental chairs, the KM Shah Charitable Trust created by him and other benefactors, has slowly metamorphosed into a health care and educational centre which can pride itself as one amongst the best in the country. Having been awarded the status of “Deemed to be University ”for having introduced a unique and innovative Evidence Based Education System, it has meticulously worked for implementing this system in true word and spirit, and in the process has created parameters for other institutions to emulate.

16 December 2015
Career as Pharma Data Entry Associate at Accenture

Accenture is a global management consulting, technology services and outsourcing company, with approximately 275,000 people serving clients in more than 120 countries. Combining unparalleled experience, comprehensive capabilities across all industries and business functions, and extensive research on the world’s most successful companies, Accenture collaborates with clients to help them become high-performance businesses and governments. The company generated net revenues of US$28.6 billion for the fiscal year ended Aug. 31, 2013.

Post: Pharma Data Entry Associate

Women who have high levels of both testosterone and estrogen in midlife may face a greater risk of developing benign tumours on the uterus called uterine fibroids than women with low levels of the hormones, reveals a new study.

[adsense:336x280:8701650588]

Amgen has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia® (denosumab), XGEVA® (denosumab) and Vectibix® (panitumumab) in 48 countries in Asia, South America, Europe, Australia and other regions throughout the world. The agreement involves key expansion markets for Amgen including Brazil, China, Colombia, Hong Kong, Israel, Singapore, South Korea, Taiwan and Thailand.